Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

739 - Prognostic implication of ERCC-1 protein expression in resected head and neck cancer

Date

09 Oct 2016

Session

Poster display

Presenters

Yoon Ho Ko

Citation

Annals of Oncology (2016) 27 (6): 328-350. 10.1093/annonc/mdw376

Authors

Y.H. Ko1, H.J. An2, C.K. Jung3, J.H. Kang4, M.S. Kim5, K.J. Cho6, H.S. Won1, D.S. Sun1

Author affiliations

  • 1 Medical Oncology, Uijeongbu St. Mary's hospital Catholic University, 480-717 - Uijeongbu-si/KR
  • 2 Medical Oncology, Suwon St. Vincent's hospital Catholic University, 442-723 - Suwon/KR
  • 3 Hospital Pathology, Seoul St. Mary's hospital Catholic University, 137-701 - Seoel/KR
  • 4 Medical Oncology, Seoul St. Mary's hospital Catholic University, 137-701 - Seoel/KR
  • 5 Surgical Oncology, Seoul St. Mary's hospital Catholic University, 137-701 - Seoel/KR
  • 6 Surgical Oncology, Uijeongbu St. Mary's hospital Catholic University, 480-717 - Uijeongbu-si/KR
More

Resources

Abstract 739

Background

The excision repair cross-complement group 1 (ERCC1) expression is related to prognosis and sensitivity to platinum-based chemotherapy in various cancers, especially lung. Platinum is the most frequently chemotherapeutic used in treatment of squamous cell carcinoma of the head and neck cancer (SCCHN), and ERCC1 has been studied as a predictive biomarker of cisplatin-containing chemo or chemo-radiotherapy. In this study, we assessed the prognostic role of ERCC1 protein expression in surgically resected SCCHN.

Methods

Between 1994 and 2012, 204 patients who were diagnosed with oropharynx or oral cavity cancer and underwent curative surgical resection were included. ERCC1 protein expression was evaluated by immunohistochemistry. Clinical and pathologic records were retrospectively reviewed.

Results

ERCC1 protein was positive in 136 (66.7%) patients. High ERCC1 expression was associated with oral cavity cancer (P 

Conclusions

ERCC1 protein expression can help to predict prognosis in surgically resected oropharynx or oral cavity SCCHN, especially in advanced stage.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

The Catholic University of Korea

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings